# GlucoShield — Phase 7C Step 2.5: Telemetry Validation Audit & Step 3 Readiness Report
**Document ID:** `GLUCOSHIELD-RPT-PHASE7C-AUDIT-2.5`  
**Timestamp:** 2026-08-28T17:36:00 Local Time  
**Author:** Lead Deep Learning & Physiological Systems Engineer  
**Status:** **INDEPENDENT AUDIT COMPLETE — CONDITIONAL GO**  

---

## 1. Executive Summary & Audit Mandate

This report provides a strict, evidence-based audit of the **Phase 7C Step 2 wearable telemetry pipeline** (`activity_telemetry/`) to determine whether the implementation, feature engineering, and experimental protocols are scientifically sound and ready to support restricted-access data acquisition (**OhioT1DM**) and future multimodal ablation experiments.

### Strict Governance Compliance:
* **GlucoShield V1 Core is Bitwise Locked:** Dataset v1.0, Neural Forecaster V1 (`models/glucoshield_neural_best.pt`), ODE Digital Twin, Hybrid Forecaster (`models/glucoshield_hybrid_best.pt`), and Phase 6 evaluation benchmarks remain untouched and permanently frozen.
* **No Premature Model Alterations:** Zero models were retrained, no channels were added to production checkpoints, and no DUA was submitted automatically.

---

## 2. Verified Facts vs. Corrected / Downgraded Claims

```
================================================================================
CORRECTED CLAIMS & SCIENTIFIC DOWNGRADES (AUDIT FINDINGS)
================================================================================
1. "Workouts Detected" -> DOWNGRADED TO: "Detected Activity Episodes"
   • Rationale: The algorithm detects contiguous active 15m intervals (e.g. daytime walking).
     Without independent gold-standard workout logs, they cannot be labeled as confirmed workouts.

2. "Step Count in D1NAMO" -> DOWNGRADED TO: "Estimated Step Proxy"
   • Rationale: The Zephyr BioHarness 3 lacks a dedicated hardware pedometer. In D1NAMO,
     steps are approximated from accelerometer Vector Magnitude Units (VMU). Only the OhioT1DM
     2018 cohort (Basis Peak) contains hardware-measured step counts.

3. "Post-Workout Glycemic Shift of -24.8 mg/dL" -> DOWNGRADED TO: "Observational Descriptive Delta"
   • Rationale: In free-living data, pre/post episode glucose deltas are confounded by meals,
     circadian baseline drift, and unrecorded basal insulin shifts. It is an observational
     descriptive statistic, NOT proof of physiological causality or forecasting superiority.

4. "Heart Rate Reserve %" -> IDENTIFIED AS REDUNDANT (r = 1.000)
   • Rationale: When resting heart rate is fixed per participant, HR reserve % is a strictly
     linear rescaling of mean heart rate. Feeding both to a neural network adds collinear redundancy.
================================================================================
```

---

## 3. Section-by-Section Scientific Audit

### A. Reproducibility Audit
* **Re-run Status:** **$100\%$ REPRODUCIBLE & DETERMINISTIC**.
* **Participants Evaluated:** 3 continuous multi-day cohorts ($1,440$ 15-minute windows, $360.0\text{ hours}$ total).
* **Valid Windows:** $1,389$ valid wearable windows ($96.5\%$ coverage), $51$ missing windows ($3.5\%$) corresponding to realistic off-wrist charging periods.
* **Output Artifacts Recomputed:**
  * `participant_coverage.csv` (`sha256: e8b941...`)
  * `feature_summary.csv` (`sha256: 74d209...`)
  * `missingness_report.csv` (`sha256: 341a0e...`)
  * `feature_correlation_matrix.csv`
  * `audited_activity_episodes.csv`

---

### B. Participant-Level Leakage & Causality Audit
1. **Strict Participant Boundary Isolation:**
   * `align_telemetry_to_15m_grid` and `compute_activity_features` operate exclusively on single-participant DataFrames.
   * Resting Heart Rate (RHR) is computed using **strictly nocturnal participant-isolated windows (02:00 to 06:00)**; no global population averaging is applied.
2. **Causal Temporal Integrity:**
   * Slicing uses exclusively past data within the causal window $(t - 15\text{m}, t]$.
   * `active_load_60m` is computed via strictly backward exponential memory ($\text{load}(t) = \sum_{k=0}^3 \gamma^k \cdot \text{steps}(t - 15k\text{m})$) with zero future lookahead.
   * `exercise_onset_flag` triggers on leading edge $0 \rightarrow 1$ transitions of present vs. past state.

---

### C. Activity Episode Audit ($N=26$ Detected Episodes)
* **Triggering Thresholds:** `steps_15m >= 150` OR `hr_reserve_pct >= 25%` OR `accel_mag_15m >= 1.15g`.
* **Findings:**
  * Daytime active blocks average $450\text{ to } 960\text{ minutes}$ when active thresholds capture routine daytime ambulation.
  * True high-intensity exercise bouts (peak $\text{HR} > 135\text{ bpm}$) occur for $45 - 60\text{ minutes}$, with mean peak HR $= 138.5\text{ bpm}$ and mean post-workout glucose delta of $-17.7\text{ mg/dL}$.
* **Audit Rule:** Future episode classification should distinguish **Sustained Ambulation** ($150-400\text{ steps/15m}$, $\text{HR} < 100\text{ bpm}$) from **Intense Exercise** ($\text{HR} > 120\text{ bpm}$, $\text{accel} > 1.3g$).

---

### D. Glycemic Shift Claim Audit
* **Formula:** $\Delta G = G_{\text{post}} - G_{\text{pre}}$, where $G_{\text{pre}}$ is the CGM reading at step $t_{\text{start}} - 15\text{m}$ and $G_{\text{post}}$ is at $t_{\text{end}} + 15\text{m}$.
* **Confounders Present:**
  1. *Postprandial Excursions:* If a meal is consumed before/during an episode, glucose may rise despite physical exertion.
  2. *Diurnal Basal Drift:* Natural hepatic glucose variations across the day.
  3. *Unrecorded Correction Boluses:* Insulin injections co-occurring with workouts.
* **Audit Verdict:** The metric is an **observational descriptive shift**. Under no circumstances should it be cited as proof that the algorithm causes glycemic improvements.

---

### E. Feature Quality & Redundancy Matrix

| Feature Name | Type | Availability in D1NAMO | Availability in OhioT1DM | Missingness | Redundancy Assessment |
|---|:---:|:---:|:---:|:---:|---|
| `hr_mean_15m` | Continuous (bpm) | **YES (1 Hz)** | **YES (2018)** | Low ($3.5\%$) | **Primary Exertion Channel (Keep)** |
| `hr_std_15m` | Continuous (bpm) | **YES (1 Hz)** | **YES (2018)** | Low ($3.5\%$) | **Intensity Volatility (Keep, low correlation $r=0.06$)** |
| `accel_mag_15m`| Continuous ($g$) | **YES (3D Accel)** | **YES (3D Accel)** | Low ($3.5\%$) | **General Body Exertion (Keep)** |
| `active_load_60m`| Continuous | **YES (Derived)** | **YES (Derived)** | Low ($3.5\%$) | **Cumulative Muscle GLUT-4 Memory (Keep)** |
| `is_active_15m`| Binary Flag | **YES (Derived)** | **YES (Derived)** | $0.0\%$ | **State Gating Flag (Keep)** |
| `sensor_missing`| Binary Flag | **YES (Quality)** | **YES (Quality)** | $0.0\%$ | **Missingness Indicator (Keep)** |
| `steps_15m` | Continuous | **Proxy Only** | **YES (Hardware)** | Low ($3.5\%$) | **Locomotion Load (Keep as Proxy in D1NAMO)** |
| `hr_reserve_pct`| Continuous ($\%$) | **YES (Derived)** | **YES (Derived)** | Low ($3.5\%$) | **REDUNDANT ($r = 1.000$ with `hr_mean_15m`). Omit from neural inputs to prevent collinearity.** |

---

### F. Baseline Model Compatibility Audit

```
===============================================================================
GLUCOSHIELD V1 (FROZEN PRODUCTION BASELINE)
===============================================================================
• Input Tensor: (Batch, 96 timesteps, 22 dynamic channels)
• Static Tensor: (Batch, 9 static biomarkers)
• Checkpoint: models/glucoshield_neural_best.pt (input_dim=22, hidden_dim=128)
• Status: 100% Frozen & Bitwise Locked

===============================================================================
FUTURE EXPERIMENTAL CLONE: GlucoShieldMultimodalV2 (STEP 3)
===============================================================================
• Input Tensor: (Batch, 96 timesteps, 28 dynamic channels)
  - 22 Core Channels (Glucose, Vel, Accel, Rolling Stats, Circadian, Insulin, IOB, Carbs, COB)
  - +6 Validated Activity Channels:
    1. steps_15m (or proxy)
    2. hr_mean_15m
    3. hr_std_15m
    4. accel_mag_15m
    5. active_load_60m
    6. sensor_missing
• Static Tensor: (Batch, 9 static biomarkers)
• Scaler Policy: RobustScaler fit STRICTLY on Training Split Patients only.
• Test Isolation Guarantee: Zero test-participant data in scalers or feature baselines.
```

---

## 4. Step 3 Controlled Ablation Protocol

To scientifically prove whether physical activity telemetry improves continuous glucose forecasting, the future Step 3 experiment must adhere to a **strict ablation protocol on the OhioT1DM dataset**:

```
[OhioT1DM Multi-Week Dataset]
              │
              ├── Train Split (8 Patients) ──> Fit Scalers on Train Only
              ├── Val Split   (2 Patients) ──> Hyperparameter Tuning & Early Stopping
              └── Test Split  (2 Patients) ──> Single Untouched Benchmark Evaluation
```

### Model Comparison Setup:
1. **Model A (Baseline Control):** GlucoShield GRU-128 trained on OhioT1DM using **ONLY the 22 base channels**.
2. **Model B (Multimodal Treatment):** Identical GRU-128 trained on OhioT1DM using **22 base + 6 validated activity channels**.

### Pre-Registered Success Criteria (Prior to Data Acquisition):
1. **Overall Error Reduction:** $\Delta\text{MAE} \ge 1.0\text{ mg/dL}$ across all test sequences.
2. **Stratified Activity Error Reduction:** $\Delta\text{MAE} \ge 3.0\text{ mg/dL}$ during active exercise windows and post-workout recovery periods ($+0$ to $+3\text{ hours}$ post-exercise).
3. **Statistical Significance:** Two-sided paired Wilcoxon signed-rank test on patient-level errors with $p < 0.05$.
4. **Rejection / Failure Criterion:** If $\Delta\text{MAE} < 0.5\text{ mg/dL}$ or $p \ge 0.05$, activity features will be rejected as non-additive for general forecasting.

---

## 5. Final Go / No-Go Decision

$$\mathbf{AUDIT \; VERDICT: \quad CONDITIONAL \; GO \; FOR \; OHIOT1DM \; DUA \; REQUEST}}$$

### Justification:
1. The telemetry alignment pipeline (`activity_telemetry/`) is **reproducible, causal, isolated, and mathematically verified**.
2. Claims have been appropriately **downgraded and scientifically disciplined** (steps are recognized as proxies in D1NAMO, detected activity episodes are separated from confirmed workouts, and glycemic shift is treated as an observational descriptive delta).
3. The future experimental ablation protocol (Model A vs. Model B) is **rigorously defined with pre-registered success and failure thresholds**.
4. **Condition:** OhioT1DM acquisition should proceed under an academic DUA solely for the controlled Step 3 ablation experiment. GlucoShield V1 remains permanently frozen as the reference baseline.

---
*Certified under Phase 7C Step 2.5 Readiness Audit protocol.*
